首页> 外国专利> BASE SEQUENCE OF pbp1 GENE OF CLINICAL ISOLATE OF HELICOBACTER PYLORI, ASSOCIATED WITH RESISTANCE TO AMOXICILLIN OF b-LACTAM-BASED ANTIBIOTIC, VARIATION OF AMINO ACID SEQUENCE BASED THEREON, VARIANT OF HELICOBACTER PYLORI HAVING THE VARIATION, DIAGNOSIS THEREOF AND METHOD FOR UTILIZING THE SAME FOR DEVELOPMENT OF THERAPEUTIC METHOD

BASE SEQUENCE OF pbp1 GENE OF CLINICAL ISOLATE OF HELICOBACTER PYLORI, ASSOCIATED WITH RESISTANCE TO AMOXICILLIN OF b-LACTAM-BASED ANTIBIOTIC, VARIATION OF AMINO ACID SEQUENCE BASED THEREON, VARIANT OF HELICOBACTER PYLORI HAVING THE VARIATION, DIAGNOSIS THEREOF AND METHOD FOR UTILIZING THE SAME FOR DEVELOPMENT OF THERAPEUTIC METHOD

机译：幽门螺杆菌临床分离株pbp1基因的碱基序列，与基于β-内酰胺的抗生素对阿米西林的耐药性有关，基于此的氨基酸序列变化，变种的幽门螺旋菌及其治疗方法及其变化治疗方法的发展

页面导航

摘要
著录项
相似文献

摘要

PROBLEM TO BE SOLVED: To clarify the gene variation of pbp1 associated with amoxicillin resistance by elucidating resistance mechanism of amoxicillin-resistant Helicobacter pylori of a clinical isolate, and to utilize the variant of the Helicobacter pylori for medicinal screening utilizing the variant of the Helicobacter pylori, diagnosis of drug-resistant bacteria based on the variation information of the amino acid sequence based on the base sequence of the pbp1 gene, and development of a new antibiotic utilizing the gene sequence information and a therapeutic method such as gene therapy.;SOLUTION: It is shown that the variation in a penicillin-binding module region present in the C-terminal side half of the pbp1 is important for the transformation to the resistant species by inducing the amoxicillin resistance in the Helicobacter pylori in vitro. As a result, the screening of a medicament having clear action mechanism, the diagnosis of the drug-resistant bacteria based on the variation information of the base sequence of the pbp1 gene and the amino acid sequence based thereon, and the development of the therapeutic method such as the new antibiotic and the gene therapy utilizing the gene sequence information can be developed.;COPYRIGHT: (C)2004,JPO

机译：解决的问题：通过阐明临床分离株对阿莫西林耐药的幽门螺杆菌的耐药机制，阐明与阿莫西林耐药相关的pbp1的基因变异，并利用幽门螺杆菌的变异体通过幽门螺杆菌的变异体进行药物筛选基于pbp1基因碱基序列的氨基酸序列变异信息诊断耐药细菌，并利用该基因序列信息和基因疗法等治疗方法开发新的抗生素。结果表明，在体外，通过诱导幽门螺杆菌中的阿莫西林耐药性，pbp1的C端一半的青霉素结合模块区域的变化对于转化为耐药菌种很重要。结果，筛选具有明确作用机理的药物，基于pbp1基因的碱基序列和基于其的氨基酸序列的变异信息诊断耐药菌，并开发治疗方法。如新抗生素的开发和利用基因序列信息的基因治疗等。COPYRIGHT：（C）2004，日本特许厅

著录项

公开/公告号JP2004121141A

专利类型
公开/公告日2004-04-22

原文格式PDF
申请/专利权人 YAMAGUCHI TECHNOLOGY LICENSING ORGANIZATION LTD;
展开▼

申请/专利号JP20020292548
发明设计人 SHIRAI BOKUKUN;NAKAZAWA AKIKO;OKITA KIWAMU;OKAMOTO KENJI;YOSHIYAMA HIRONORI;
展开▼

申请日2002-10-04
分类号C12N15/09;A61K45/00;A61P31/04;C12N1/20;C12N1/21;C12N15/01;C12Q1/02;G01N33/15;G01N33/50;G01N33/53;G01N33/566;
国家 JP
入库时间 2022-08-21 23:31:11

相似文献

专利
外文文献